Literature DB >> 25450212

Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity.

Kavya Anjani1, Marie Lhomme2, Nataliya Sokolovska1, Christine Poitou1, Judith Aron-Wisnewsky1, Jean-Luc Bouillot3, Philippe Lesnik4, Pierre Bedossa5, Anatol Kontush4, Karine Clement1, Isabelle Dugail6, Joan Tordjman7.   

Abstract

BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is characterized by steatosis, lobular inflammation, hepatocyte ballooning with fibrosis in severe cases, and high prevalence in obesity. We aimed at defining NASH signature in morbid obesity by mass spectrometry-based lipidomic analysis.
METHODS: We analyzed systemic blood before and 12 months after bariatric surgery, along with portal blood and adipose tissue lipid efflux collected from obese women at the time of surgery (9 structural classes, 150 species).
RESULTS: Increased concentrations of several glycerophosphocholines (PC), glycerophosphoethanolamines (PE), glycerophosphoinositols (PI), glycerophosphoglycerols (PG), lyso-glycerophosphocholines (LPC), and ceramides (Cer) were detected in systemic circulation of NASH subjects. Post-surgery weight loss (12 months) improved the levels of liver enzymes, as well as several lipids, but most PG and Cer species remained elevated. Analysis of lipids from hepatic portal system at the time of surgery revealed limited lipid alterations compared to systemic circulation, but PG and PE classes were found significantly increased in NASH subjects. We evaluated the contribution of visceral adipose tissue to lipid alterations in portal circulation by measuring adipose tissue lipid efflux ex vivo, and observed only minor alterations in NASH subjects. Interestingly, integration of clinical and lipidomic data (portal and systemic) led us to define a NASH signature in which lipids and clinical parameters are equal contributors.
CONCLUSIONS: Circulatory (portal and systemic) phospholipid profiling and clinical data defines NASH signature in morbid obesity. We report weak contribution of visceral adipose tissue to NASH-related portal lipid alterations, suggesting possible contribution from other organs draining into hepatic portal system.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Glycerophosphatidylethanolamines; Glycerophosphatidylglycerols; Lipidomics; Visceral adipose tissue

Mesh:

Substances:

Year:  2014        PMID: 25450212     DOI: 10.1016/j.jhep.2014.11.002

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  42 in total

1.  Serum lipidomics reveals early differential effects of gastric bypass compared with banding on phospholipids and sphingolipids independent of differences in weight loss.

Authors:  B D Kayser; M Lhomme; M C Dao; F Ichou; J-L Bouillot; E Prifti; A Kontush; J-M Chevallier; J Aron-Wisnewsky; I Dugail; K Clément
Journal:  Int J Obes (Lond)       Date:  2017-03-10       Impact factor: 5.095

Review 2.  Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.

Authors:  Arka De; Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2019-09-20

3.  Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism.

Authors:  Alexandra Collin de l'Hortet; Kazuki Takeishi; Jorge Guzman-Lepe; Kazutoyo Morita; Abhinav Achreja; Branimir Popovic; Yang Wang; Kan Handa; Anjali Mittal; Noah Meurs; Ziwen Zhu; Frank Weinberg; Michael Salomon; Ira J Fox; Chu-Xia Deng; Deepak Nagrath; Alejandro Soto-Gutierrez
Journal:  Cell Metab       Date:  2019-08-06       Impact factor: 27.287

4.  Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver.

Authors:  Alexandra Feldman; Sebastian K Eder; Thomas K Felder; Lyudmyla Kedenko; Bernhard Paulweber; Andreas Stadlmayr; Ursula Huber-Schönauer; David Niederseer; Felix Stickel; Simon Auer; Elisabeth Haschke-Becher; Wolfgang Patsch; Christian Datz; Elmar Aigner
Journal:  Am J Gastroenterol       Date:  2016-08-16       Impact factor: 10.864

5.  A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy.

Authors:  Bruno Ramos-Molina; Daniel Castellano-Castillo; Oscar Pastor; Luis Ocaña-Wilhelmi; Diego Fernández-García; Manuel Romero-Gómez; Fernando Cardona; Francisco J Tinahones
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

Review 6.  Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.

Authors:  Manoela Mota; Bubu A Banini; Sophie C Cazanave; Arun J Sanyal
Journal:  Metabolism       Date:  2016-03-03       Impact factor: 8.694

7.  Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression.

Authors:  Kang-Yu Peng; Matthew J Watt; Sander Rensen; Jan Willem Greve; Kevin Huynh; Kaushala S Jayawardana; Peter J Meikle; Ruth C R Meex
Journal:  J Lipid Res       Date:  2018-07-24       Impact factor: 5.922

8.  Stereospecific synthesis of phosphatidylglycerol using a cyanoethyl phosphoramidite precursor.

Authors:  Zachary J Struzik; Ashley N Weerts; Judith Storch; David H Thompson
Journal:  Chem Phys Lipids       Date:  2020-06-11       Impact factor: 3.329

Review 9.  Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review.

Authors:  Natalia Rosso; Adam M Stephenson; Pablo J Giraudi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2021-04

10.  Phosphatidylglycerols are induced by gut dysbiosis and inflammation, and favorably modulate adipose tissue remodeling in obesity.

Authors:  Brandon D Kayser; Marie Lhomme; Edi Prifti; Carla Da Cunha; Florian Marquet; Florian Chain; Isabelle Naas; Véronique Pelloux; Maria-Carlota Dao; Anatol Kontush; Salwa W Rizkalla; Judith Aron-Wisnewsky; Luis G Bermúdez-Humarán; Fiona Oakley; Philippe Langella; Karine Clément; Isabelle Dugail
Journal:  FASEB J       Date:  2019-01-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.